Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01479283 · ClinicalTrials.gov registry record · Phase 3
Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY)
A Phase 3 study, sponsored by McMaster University.
- Completed
- Registry status
- Phase 3
- Development phase
- 602
- Enrollment target
NCT01479283 is a Phase 3 study that has completed, run by McMaster University. The registered enrollment target is 602 participants.
The verdict
NCT01479283, a Phase 3 study, has completed, sponsored by McMaster University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 602 participants
- Enrollment target
Study Summary
The Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) trial is the first ever international multi-center randomized controlled trial in bone cancer surgery. In order to avoid amputation for bone cancer in the leg, complex limb-saving operations are performed. However, infections with devastating complications following surgery are common. Surgeons from across the world will randomize patients to receive either short- or long-duration antibiotic regimens after surgery with the goal of identifying the best regimen to reduce these infections.
Interventions
- DRUG 24-Hour Prophylactic Cefazolin* Antibiotic Regimen
- DRUG 5-Days Prophylactic Cefazolin* Antibiotic Regimen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 602 participants |
| Start Date | 2013-01 |
| Est. Completion | 2021-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01479283
The ClinicalTrials.gov registry entry for NCT01479283 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 602 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is McMaster University, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 24-Hour Prophylactic Cefazolin* Antibiotic Regimen is the first listed.
NCT01479283 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01479283 about?
NCT01479283 is a clinical study titled "Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY)". The Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) trial is the first ever international multi-center randomized controlled trial in bone cancer surgery. In order to avoid amputation for bone cancer in the leg, complex limb-saving operations are performed. However, infections with devast...
What is the current status of trial NCT01479283?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 602 participants. The study started on 2013-01. Estimated completion is 2021-03.
What interventions are being tested in trial NCT01479283?
The interventions under investigation include: 24-Hour Prophylactic Cefazolin* Antibiotic Regimen (DRUG), 5-Days Prophylactic Cefazolin* Antibiotic Regimen (DRUG).
Who is sponsoring clinical trial NCT01479283?
This trial is sponsored by McMaster University, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.